IE 11 is a very old Browser and it`s not supported on this site

Consolidated statement of cash flow

(in CHF 1 000)

 

 

Notes

 

01.01.–30.09.2021

 

01.01.–30.09.2020

Cash flows from operating activities

 

 

 

 

 

 

Proceeds from sales of securities

 

4

 

846 534

 

540 958

Purchase of securities

 

4

 

(795 084)

 

(427 471)

Dividend receipts

 

 

 

 

243

Interest receipts

 

 

 

 

7

Payments for services

 

 

 

(44 699)

 

(35 044)

Income taxes paid

 

 

 

(112)

 

(45)

Total cash flows from operating activities

 

 

 

6 639

 

78 648

 

 

 

 

 

 

 

Cash flows from financing activities

 

 

 

 

 

 

Dividend

 

 

 

(199 440)

 

(188 360)

Proceeds from sales of treasury shares

 

6

 

9 653

 

Purchase of treasury shares

 

6

 

(5 622)

 

Borrowing of bank loans

 

5

 

185 000

 

95 000

Interest payments

 

 

 

(648)

 

(683)

Total cash flows from financing activities

 

 

 

(11 057)

 

(94 043)

 

 

 

 

 

 

 

Foreign exchange difference

 

 

 

(623)

 

(429)

Change in cash and cash equivalents

 

 

 

(5 041)

 

(15 824)

 

 

 

 

 

 

 

Cash and cash equivalents at the beginning of the period

 

 

 

6 816

 

30 707

 

 

 

 

 

 

 

Cash and cash equivalents at the end of the period

 

 

 

1 775

 

14 883

The notes are an integral part of the condensed consolidated interim financial statements.

BB Biotech AG uses cookies to improve website usability and ensure the best possible user experience.Use of cookies & disclaimer